<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
NEOTHERAPEUTICS, INC.
---------------------
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
-----------------------------
(Title of Class of Securities)
640-656104
----------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act,
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
SCHEDULE 13G
- --------------------- -----------------
CUSIP NO. 640-656104 PAGE 2 OF 5 PAGES
- --------------------- -----------------
===============================================================================
1 NAME OF REPORTING PERSONS/
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Alvin J. Glasky, Ph.D.
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)
(a) [ ]
N/A
(b) [ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
- -------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF
SHARES 1, 307,911
------------------------------------------------
6 SHARED VOTING POWER
REPORTING
BENEFICIALLY -0-
------------------------------------------------
7 SOLE DISPOSITIVE POWER
OWNED BY
EACH 1,307,911
------------------------------------------------
8 SHARED DISPOSITIVE POWER
PERSON
WITH -0-
- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,307,911
- -------------------------------------------------------------------------------
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X|
(SEE INSTRUCTIONS)
- -------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
23.93%
- -------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
===============================================================================
<PAGE> 3
ITEM 1.
(a) NAME OF ISSUER:
---------------
NeoTherapeutics, Inc.
(b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
------------------------------------------------
157 Technology Drive
Irvine, CA 92618
ITEM 2. (a) NAME OF PERSON FILING:
----------------------
Alvin J. Glasky, Ph.D.
(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE:
-------------------------------------
157 Technology Drive
Irvine, CA 92618
(c) CITIZENSHIP: United States of America
------------
(c) TITLE OF CLASS OF SECURITIES:
-----------------------------
Common Stock, $.001 par value per share
(d) CUSIP NUMBER:
-------------
640-656104
ITEM 3. If this statement is filed pursuant Rule 13d-1(b), or 13d-2(b), check
whether the person filing is a: N/A
(a) [ ] Broker or dealer registered under Section 15 of the Act.
(b) [ ] Bank as defined in Section 3(a)(6) of the Act.
(c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act.
(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act.
(e) [ ] Investment Advisor registered under Section 203 of the
Investment Advisors Act of 1940.
(f) [ ] Employee Benefit Plan, Pension Fund which is subject to
the provisions of the Employee Retirement Income Security
Act of 1974 or Endowment Fund: see Rule
13d-1(b)(1)(ii)(F).
(g) [ ] Parent Holding Company, in accordance with Rule
13d-1(b)(ii)(G) (Note, See Item 7).
(h) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(H).
<PAGE> 4
ITEM 4. OWNERSHIP.
If the percent of the class owned, as of December 31, 1997, or as of
the last day of any month described in Rule 13d-1(b)(2), if applicable, exceeds
five percent, provide the following information as of that date and identify
those shares which there is a right to acquire.
(a) Amount beneficially owned: 1,307,911*
(b) Percent of Class: 23.93%
(c) Number of shares as to such person has:
(i) Sole power to vote or to direct the vote: 1,307,911*
(ii) Shared power to vote or to direct to vote: -0-
(iii) Sole power to dispose or to direct the
disposition of: 1,307,911*
(iv) Shared power to dispose or to direct the
disposition of: -0-
------------
*Includes 88,173 shares currently issuable under the exercise of a
warrant, as well as 25,000 shares of common stock which can be
acquired upon the exercise of outstanding options within 60 days of
December 31, 1997, held by Dr. Glasky. Excludes 49,462 shares owned by
Dr. Glasky's wife, as to which he disclaims beneficial ownership.
ITEM 5. OWNERSHIP OF 5% OR LESS OF CLASS.
If this statement is being filed to report the fact that as of the
date hereof the reported person has ceased to be the beneficial owner of more
than 5% of the class of securities, check the following: [ ]
ITEM 6. OWNERSHIP OF MORE THAN 5% ON BEHALF OF ANOTHER PERSON.
N/A
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
N/A
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
N/A
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
N/A
ITEM 10. CERTIFICATION.
N/A
<PAGE> 5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: February 10, 1998 By: /s/ Alvin J. Glasky, Ph.D.
-------------------------------
Alvin J. Glasky, Ph.D.
